Chronic Obstructive Pulmonary Disease (COPD) Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | AstraZeneca Plc, GSK plc, MD Healthcare Inc, Chiesi Farmaceutici SpA, F.

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Obstructive Pulmonary Disease pipeline constitutes 65+ key companies continuously working towards developing 70+ Chronic Obstructive Pulmonary Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Chronic Obstructive Pulmonary Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Obstructive Pulmonary Disease Market.

The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report: https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Chronic Obstructive Pulmonary Disease treatment therapies with a considerable amount of success over the years.
• Chronic Obstructive Pulmonary Disease companies working in the treatment market are Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tethrex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others, are developing therapies for the Chronic Obstructive Pulmonary Disease treatment
• Emerging Chronic Obstructive Pulmonary Disease therapies in the different phases of clinical trials are- Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others are expected to have a significant impact on the Chronic Obstructive Pulmonary Disease market in the coming years.
• In December 2023, Regeneron Pharmaceuticals and Sanofi have reported that the Phase III NOTUS trial (NCT04456673), which assessed dupixent (dupilumab) for chronic obstructive pulmonary disease (COPD), demonstrated a significant reduction in exacerbations. This aligns with the favorable outcomes observed in the BOREAS trial. The NOTUS trial also affirmed that dupixent treatment resulted in rapid and substantial enhancements in lung function within 12 weeks, and these improvements were sustained at 52 weeks. If granted approval, this candidate has the potential to be the initial approved biologic for COPD.

Chronic Obstructive Pulmonary Disease Overview
Chronic Obstructive Pulmonary Disease (COPD) is a progressive and chronic respiratory condition characterized by persistent airflow limitation and difficulty breathing. COPD is an umbrella term that includes several respiratory disorders, with the most common forms being chronic bronchitis and emphysema.

Get a Free Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Chronic Obstructive Pulmonary Disease Drugs Under Different Phases of Clinical Development Include:
• Astegolimab (MSTT1041A, AMG 282, RG6149): Genentech, Inc.
• SB240563 (Mepolizumab)/NUCALA: GlaxoSmithKline
• Ensifentrine (RPL554): Verona Pharma plc
• Itepekimab/SAR440340/REGN3500: Regeneron Pharmaceuticals/Sanofi
• Dupilumab/SAR231893 (Dupixent): Regeneron Pharmaceuticals/Sanofi
• Tozorakimab (MEDI3506): AstraZeneca/MedImmune LLC
• FASENRA (Benralizumab): AstraZeneca
• Tezspire (Tezepelumab): AstraZeneca
• EP395: EpiEndo Pharmaceuticals
• SelK2: Tethrex Pharmaceuticals
• Mitiperstat (AZD4831): AstraZeneca
• CHF6001/Tanimilast: Chiesi Farmaceutici S.p.A.
• SNG001 (IFN-β): Synairgen Research Ltd.
• Acumapimod (BCT-197): Mereo Biopharma
• Zofin: Organicell Regenerative Medicine
• PUL-042: Pulmotect, Inc.
• MV130: Inmunotek S.L.
• GSK3923868: GlaxoSmithKline
• PUR1800: PULMATRiX
• GRC 39815: GLENMARK PHARMACEUTICALS LTD
• DMX-700: Dimerix Limited

Chronic Obstructive Pulmonary Disease Route of Administration
Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular

Chronic Obstructive Pulmonary Disease Molecule Type
Chronic Obstructive Pulmonary Disease Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide

Chronic Obstructive Pulmonary Disease Pipeline Therapeutics Assessment
• Chronic Obstructive Pulmonary Disease Assessment by Product Type
• Chronic Obstructive Pulmonary Disease By Stage and Product Type
• Chronic Obstructive Pulmonary Disease Assessment by Route of Administration
• Chronic Obstructive Pulmonary Disease By Stage and Route of Administration
• Chronic Obstructive Pulmonary Disease Assessment by Molecule Type
• Chronic Obstructive Pulmonary Disease by Stage and Molecule Type

DelveInsight's Chronic Obstructive Pulmonary Disease Report covers around 70+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Chronic Obstructive Pulmonary Disease product details are provided in the report. Download the Chronic Obstructive Pulmonary Disease pipeline report to learn more about the emerging Chronic Obstructive Pulmonary Disease therapies at:
https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Chronic Obstructive Pulmonary Disease Therapeutics Market include:
Key companies developing therapies for Chronic Obstructive Pulmonary Disease are - AstraZeneca Plc, GSK plc, MD Healthcare Inc, Chiesi Farmaceutici SpA, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd, Mariposa Health Ltd, Respiratorius AB, Crystec Ltd, Foresee Pharmaceuticals Co Ltd, iCeutica Inc, Korea United Pharm Inc, LTT Bio-Pharma Co Ltd, Aquilon Pharmaceuticals SA, and Boehringer Ingelheim International GmbH, and others.

Chronic Obstructive Pulmonary Disease Pipeline Analysis:
The Chronic Obstructive Pulmonary Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Obstructive Pulmonary Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Obstructive Pulmonary Disease Treatment.
• Chronic Obstructive Pulmonary Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Obstructive Pulmonary Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Obstructive Pulmonary Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease drugs and therapies-
https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Obstructive Pulmonary Disease Pipeline Market Drivers
• Rising disease burden associated with COPD, increasing focus on therapy development, favorable insurance coverage for COPD treatment are some of the important factors that are fueling the Chronic Obstructive Pulmonary Disease Market.

Chronic Obstructive Pulmonary Disease Pipeline Market Barriers
• However, Concerns regarding the long term use of current ICS/LABA inhalers, poor regimen adherence by patients, treatment costs and other factors are creating obstacles in the Chronic Obstructive Pulmonary Disease Market growth.

Scope of Chronic Obstructive Pulmonary Disease Pipeline Drug Insight
• Coverage: Global
• Key Chronic Obstructive Pulmonary Disease Companies: Genentech, Inc., GlaxoSmithKline, Verona Pharma plc, Regeneron Pharmaceuticals, Sanofi, MedImmune LLC, EpiEndo Pharmaceuticals, Tethrex Pharmaceuticals, AstraZeneca, Chiesi Farmaceutici S.p.A., Synairgen Research Ltd., Mereo Biopharma, Organicell Regenerative Medicine, Pulmotect, Inc., Inmunotek S.L., PULMATRiX, GLENMARK PHARMACEUTICALS LTD, Dimerix Limited, ProterixBio, and others
• Key Chronic Obstructive Pulmonary Disease Therapies: Astegolimab (MSTT1041A, AMG 282, RG6149), SB240563 (Mepolizumab)/NUCALA, Ensifentrine (RPL554), Itepekimab/SAR440340/REGN3500, Dupilumab/SAR231893 (Dupixent), Tozorakimab (MEDI3506), FASENRA (Benralizumab), Tezspire (Tezepelumab), EP395, SelK2, Mitiperstat (AZD4831), CHF6001/Tanimilast, SNG001 (IFN-β), Acumapimod (BCT-197), Zofin, PUL-042, MV130, GSK3923868, PUR1800, GRC 39815, DMX-700, and others
• Chronic Obstructive Pulmonary Disease Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and Chronic Obstructive Pulmonary Disease emerging therapies
• Chronic Obstructive Pulmonary Disease Market Dynamics: Chronic Obstructive Pulmonary Disease market drivers and Chronic Obstructive Pulmonary Disease market barriers

Request for Sample PDF Report for Chronic Obstructive Pulmonary Disease Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Chronic Obstructive Pulmonary Disease Report Introduction
2. Chronic Obstructive Pulmonary Disease Executive Summary
3. Chronic Obstructive Pulmonary Disease Overview
4. Chronic Obstructive Pulmonary Disease- Analytical Perspective In-depth Commercial Assessment
5. Chronic Obstructive Pulmonary Disease Pipeline Therapeutics
6. Chronic Obstructive Pulmonary Disease Late Stage Products (Phase II/III)
7. Chronic Obstructive Pulmonary Disease Mid Stage Products (Phase II)
8. Chronic Obstructive Pulmonary Disease Early Stage Products (Phase I)
9. Chronic Obstructive Pulmonary Disease Preclinical Stage Products
10. Chronic Obstructive Pulmonary Disease Therapeutics Assessment
11. Chronic Obstructive Pulmonary Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Chronic Obstructive Pulmonary Disease Key Companies
14. Chronic Obstructive Pulmonary Disease Key Products
15. Chronic Obstructive Pulmonary Disease Unmet Needs
16 . Chronic Obstructive Pulmonary Disease Market Drivers and Barriers
17. Chronic Obstructive Pulmonary Disease Future Perspectives and Conclusion
18. Chronic Obstructive Pulmonary Disease Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Chronic Obstructive Pulmonary Disease Market https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Chronic Obstructive Pulmonary Disease Epidemiology https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disorder-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Chronic Obstructive Pulmonary Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.